- Home
- KALA vs ICCC Comparison
KALA vs ICCC Comparison
Compare KALA & ICCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KALA
- ICCC
- Stock Information
- Founded
- KALA 2009
- ICCC 1982
- Country
- KALA United States
- ICCC United States
- Employees
- KALA N/A
- ICCC N/A
- Industry
- KALA Biotechnology: Pharmaceutical Preparations
- ICCC Biotechnology: Pharmaceutical Preparations
- Sector
- KALA Health Care
- ICCC Health Care
- Exchange
- KALA Nasdaq
- ICCC Nasdaq
- Market Cap
- KALA 31.3M
- ICCC 28.0M
- IPO Year
- KALA 2017
- ICCC 1987
- Fundamental
- Price
- KALA $5.92
- ICCC $4.41
- Analyst Decision
- KALA Strong Buy
- ICCC
- Analyst Count
- KALA 2
- ICCC 0
- Target Price
- KALA $15.00
- ICCC N/A
- AVG Volume (30 Days)
- KALA 31.3K
- ICCC 23.7K
- Earning Date
- KALA 11-12-2024
- ICCC 11-13-2024
- Dividend Yield
- KALA N/A
- ICCC N/A
- EPS Growth
- KALA N/A
- ICCC N/A
- EPS
- KALA N/A
- ICCC N/A
- Revenue
- KALA N/A
- ICCC $23,838,001.00
- Revenue This Year
- KALA N/A
- ICCC N/A
- Revenue Next Year
- KALA N/A
- ICCC N/A
- P/E Ratio
- KALA N/A
- ICCC N/A
- Revenue Growth
- KALA N/A
- ICCC 46.37
- 52 Week Low
- KALA $4.21
- ICCC $3.34
- 52 Week High
- KALA $9.25
- ICCC $5.82
- Technical
- Relative Strength Index (RSI)
- KALA 41.69
- ICCC 51.68
- Support Level
- KALA $5.67
- ICCC $4.43
- Resistance Level
- KALA $6.23
- ICCC $5.23
- Average True Range (ATR)
- KALA 0.31
- ICCC 0.50
- MACD
- KALA -0.07
- ICCC -0.04
- Stochastic Oscillator
- KALA 21.55
- ICCC 13.50
About KALA KALA BIO Inc.
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.
About ICCC ImmuCell Corporation
ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.